丹參酮Ⅱa磺酸鈉微量雜質(zhì)的分離與結(jié)構(gòu)鑒定.doc
約19頁(yè)DOC格式手機(jī)打開(kāi)展開(kāi)
丹參酮Ⅱa磺酸鈉微量雜質(zhì)的分離與結(jié)構(gòu)鑒定,摘要:丹參酮iia磺酸鈉,是從藥材丹參中提取的主要脂溶性有效成分丹參酮iia經(jīng)磺化反應(yīng)后形成的一種水溶性鈉鹽,由于磺酸基的引入,提高了丹參酮iia的水溶性,在治療冠心病、心絞痛、心肌梗塞等疾病方面顯示出與丹參酮iia所無(wú)法比擬的優(yōu)越性,成為主要的心血管類(lèi)中藥。目前從丹參中提取丹參...


內(nèi)容介紹
此文檔由會(huì)員 小花仙66 發(fā)布
丹參酮Ⅱa磺酸鈉微量雜質(zhì)的分離與結(jié)構(gòu)鑒定
摘要:丹參酮IIa磺酸鈉,是從藥材丹參中提取的主要脂溶性有效成分丹參酮IIa經(jīng)磺化反應(yīng)后形成的一種水溶性鈉鹽,由于磺酸基的引入,提高了丹參酮IIa的水溶性,在治療冠心病、心絞痛、心肌梗塞等疾病方面顯示出與丹參酮IIa所無(wú)法比擬的優(yōu)越性,成為主要的心血管類(lèi)中藥。
目前從丹參中提取丹參酮IIa的方法和藥理活性研究較多,但對(duì)于丹參酮IIa磺酸鈉雜質(zhì)的研究很少,原料中的微量雜質(zhì)成分的研究還是空白。在對(duì)丹參酮IIa磺酸鈉的藥理作用,在藥物代謝動(dòng)力學(xué)和相關(guān)文獻(xiàn)報(bào)導(dǎo)的制備工藝等進(jìn)行綜合考察的基礎(chǔ)上本課題采用色譜及波譜方法對(duì)丹參酮IIa磺酸鈉進(jìn)行微量雜質(zhì)的分離及結(jié)構(gòu)鑒定。同時(shí),本文建立了高效液相色譜法測(cè)定原料藥丹參酮ⅡA磺酸鈉微量成份含量的方法,可用來(lái)對(duì)原料藥和制劑進(jìn)行質(zhì)量控制。
關(guān)鍵詞:羥基丹參酮IIa磺酸鈉;丹參酮IIa磺酸鈉;丹參酮IIa;分離;結(jié)構(gòu)鑒定
Separation of Microimpurity and Identification of
Sodium Tanshinone IIa Sulfonate
Abstract: Salvia miltiorrhiza is one of the most important tradition Chinese medicinal materials that possess the function of both promoting blood flow and removing blood stasis with anti-coronary artery disease. The consumed quantity only in the aspect of injection has been exceeded 2 billion dosages every year. However, because the undetermined active ingredients and relaxed index of quality control induced the instable effects of clinic traterment, and, moreover, usually adverse functions, which lead salvia miltiorrhiza unable to accommodate requirement of contemporary Chinese medicinal materials melting world.
Sulfotanshinone sodium is asodium chloride of water-solubility after sulfonating tanshinone IIa of liposolubility active ingredien tabstraeted in salvia miltiorrhiza.It is an effective medicine of angiocardiopathy to treat coronary artery disease, anginacordis,and myocardial infarction.The amount of clincal utilization continuous.
increasing with the high proportion of patients of angiocardiopathy induces raw material resource of salvia miltiorrhiza insufficient in China. So it becomes an extensive focus point in fharmaceutical factory that sufficient utilize and cut down uymost dissipation resource of salvia miltiorrhiza.
Keywords:1-Hydroxy-Tanshinone IIa sulfonate ;
sodium tanshinoneⅡA sulphonate(STS);tanshinoneIIa;separation;identification
目 錄
摘要…………………………………………………………………………3
前言…………………………………………………………………………5
第一章 文獻(xiàn)綜述…………………………………………………………6
1.1 丹參形態(tài)………………………………………………………………6
1.2 丹參的化學(xué)成份及其藥理作用………………………………………7
1.3 丹參酮IIa磺酸鈉的藥理作用及研究現(xiàn)狀…………………………8
第二章 原料藥中微量成分的分離及結(jié)構(gòu)鑒定…………………………13
2.1 實(shí)驗(yàn)方法………………………………………………………………13
2.1.1實(shí)驗(yàn)儀器……………………………………………………………13
2.1.2實(shí)驗(yàn)試劑……………………………………………………………13
2.1.3原料藥中微量成分的分離…………………………………………13
2.2 目標(biāo)化合物的結(jié)構(gòu)鑒定………………………………………………15
參考文獻(xiàn)……………………………………………………………………17
致謝…………………………………………………………………………18
摘要:丹參酮IIa磺酸鈉,是從藥材丹參中提取的主要脂溶性有效成分丹參酮IIa經(jīng)磺化反應(yīng)后形成的一種水溶性鈉鹽,由于磺酸基的引入,提高了丹參酮IIa的水溶性,在治療冠心病、心絞痛、心肌梗塞等疾病方面顯示出與丹參酮IIa所無(wú)法比擬的優(yōu)越性,成為主要的心血管類(lèi)中藥。
目前從丹參中提取丹參酮IIa的方法和藥理活性研究較多,但對(duì)于丹參酮IIa磺酸鈉雜質(zhì)的研究很少,原料中的微量雜質(zhì)成分的研究還是空白。在對(duì)丹參酮IIa磺酸鈉的藥理作用,在藥物代謝動(dòng)力學(xué)和相關(guān)文獻(xiàn)報(bào)導(dǎo)的制備工藝等進(jìn)行綜合考察的基礎(chǔ)上本課題采用色譜及波譜方法對(duì)丹參酮IIa磺酸鈉進(jìn)行微量雜質(zhì)的分離及結(jié)構(gòu)鑒定。同時(shí),本文建立了高效液相色譜法測(cè)定原料藥丹參酮ⅡA磺酸鈉微量成份含量的方法,可用來(lái)對(duì)原料藥和制劑進(jìn)行質(zhì)量控制。
關(guān)鍵詞:羥基丹參酮IIa磺酸鈉;丹參酮IIa磺酸鈉;丹參酮IIa;分離;結(jié)構(gòu)鑒定
Separation of Microimpurity and Identification of
Sodium Tanshinone IIa Sulfonate
Abstract: Salvia miltiorrhiza is one of the most important tradition Chinese medicinal materials that possess the function of both promoting blood flow and removing blood stasis with anti-coronary artery disease. The consumed quantity only in the aspect of injection has been exceeded 2 billion dosages every year. However, because the undetermined active ingredients and relaxed index of quality control induced the instable effects of clinic traterment, and, moreover, usually adverse functions, which lead salvia miltiorrhiza unable to accommodate requirement of contemporary Chinese medicinal materials melting world.
Sulfotanshinone sodium is asodium chloride of water-solubility after sulfonating tanshinone IIa of liposolubility active ingredien tabstraeted in salvia miltiorrhiza.It is an effective medicine of angiocardiopathy to treat coronary artery disease, anginacordis,and myocardial infarction.The amount of clincal utilization continuous.
increasing with the high proportion of patients of angiocardiopathy induces raw material resource of salvia miltiorrhiza insufficient in China. So it becomes an extensive focus point in fharmaceutical factory that sufficient utilize and cut down uymost dissipation resource of salvia miltiorrhiza.
Keywords:1-Hydroxy-Tanshinone IIa sulfonate ;
sodium tanshinoneⅡA sulphonate(STS);tanshinoneIIa;separation;identification
目 錄
摘要…………………………………………………………………………3
前言…………………………………………………………………………5
第一章 文獻(xiàn)綜述…………………………………………………………6
1.1 丹參形態(tài)………………………………………………………………6
1.2 丹參的化學(xué)成份及其藥理作用………………………………………7
1.3 丹參酮IIa磺酸鈉的藥理作用及研究現(xiàn)狀…………………………8
第二章 原料藥中微量成分的分離及結(jié)構(gòu)鑒定…………………………13
2.1 實(shí)驗(yàn)方法………………………………………………………………13
2.1.1實(shí)驗(yàn)儀器……………………………………………………………13
2.1.2實(shí)驗(yàn)試劑……………………………………………………………13
2.1.3原料藥中微量成分的分離…………………………………………13
2.2 目標(biāo)化合物的結(jié)構(gòu)鑒定………………………………………………15
參考文獻(xiàn)……………………………………………………………………17
致謝…………………………………………………………………………18
TA們正在看...
- (公交總站、車(chē)站、貨運(yùn)站)交通場(chǎng)站安全管理.ppt
- (公交總站、汽車(chē)站、貨嘗車(chē)站)場(chǎng)站消防安全.pdf
- (交通場(chǎng)站、公交總站、車(chē)站、交通綜合樞紐)運(yùn)營(yíng)...doc
- 汽車(chē)站現(xiàn)場(chǎng)安全檢查表.xls
- 山東省重點(diǎn)監(jiān)控特種設(shè)備安全監(jiān)督管理規(guī)定.doc
- 深圳經(jīng)濟(jì)特區(qū)房屋安全條例(草案稿).doc
- 深圳市新葵壩路項(xiàng)目建議書(shū)專(zhuān)家評(píng)審意見(jiàn)(投資15億...pdf
- 特種設(shè)備安全檢查自查表(壓力容器、電梯、起重機(jī)...doc
- (xx公司)安全生產(chǎn)管理制度文本(范本).doc
- 安全生產(chǎn)管理規(guī)章制度和操作規(guī)程清單(共37頁(yè)).doc